Current Research Studies

Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. once weekly versus placebo in children and adolescents with type 2 diabetes

REIMAGINE YOUNG

Phase: III
Clinicaltrials.gov ID: NCT07282613

What is the goal of the study?

A research study to see how much CagriSema lowers blood sugar and body weight compared to placebo in children and adolescents with type 2 diabetes

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Kalie Tommerdahl
Study Team Member: Kevin Bocek, [email protected]